BCRX•benzinga•
Cantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2025 by benzinga